Company: DMAAR
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-046061
Chunk: 69

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 8
Chunk 69
---
NOTE 8 — FAIR VALUE MEASUREMENTS

The fair value of the Company’s financial
assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale
of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the
measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of
observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities
based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

    Level 1:   
    Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

    Level 2:
    Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

    Level 3:
    Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

16

DRUGS MADE IN AMERICA ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2025

(Unaudited)

The following table presents information about
the Company’s financial instruments that are measured at fair value as of March 31, 2025 and January 29, 2025 and indicates the
fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. There were no assets or liabilities measured
at fair value as of December 31, 2024.

    Level 
    March 31, 2025 
  
    Assets: 

    Investments held in Trust Account 
    1 
    $232,735,468 

    Level 
    January 29, 2025 
  
    Assets: 

    Investments held in Trust Account 
    1 
    $201,000,000 
  
    Liabilities: 

    Over-allotment option 
    3 
    $305,179 
  
    Equity: 

    Fair value of Public Rights for